Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR: SYD-101 for Myopia in Children
NCT03918915Phase 3Completed
- Sponsor
- Sydnexis Inc.
- Start
- Apr 2019
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of SYD-101 in myopia (3 arms), sponsored by Sydnexis Inc. Primary endpoint: Myopic Progression <-0.75 Diopters at 36 months. Started Apr 2019; status: completed.
02
Drugs
SYD-101
03
Conditions
myopia
Beyond the preview
Go deeper on NCT03918915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03918915.